Italy to improve regions uptake of anticancer reimbursement decisions
This article was originally published in Scrip
Italy's ministry of health is going to sign an agreement with the country's 21 regions to stop them from delaying the uptake into their hospital positive lists the central reimbursement decisions made by the Italian Medicines Agency, AIFA, on "innovative" drugs, which usually includes expensive anticancers. The agreement, which was drawn up by the ministry of health, is expected to be signed within the next two months.
You may also be interested in...
The US Food and Drug Administration recently signalled its desire to work more closely with other drug regulators in assessing the quality of pharmaceutical manufacturing facilities around the world.
It seems as if the US FDA is softening its stance on assessing the quality of pharmaceutical manufacturing facilities around the world in future, with an apparent desire to work more closely with other drug regulators. However, incorporating the regulators from countries such as India, China and Japan into a global inspectorate still looks problematical.
Large pharmaceutical companies and Médecins sans Frontières may not often see eye-to-eye over access to medicines in poor countries. But it seems as if industry and the humanitarian body, a prominent critic, do agree that competition works in improving access to vaccines, even though they don't agree about the mechanisms of price setting.